I find it hard to believe there won't be multiple interested parties for:
bisPSMA construct, which has nearly proven significantly higher uptake for diagnostics in their bcr combat trial
Cu64/67 pairing that is easily switched in their SAR cage, thus eliminating concerns of diagnostic/therapeutic targeting as well as keeping the payload specific to target.
Grpr targeting allowing for Bombesin and eventually breast
click tech antibody allowing for a massive potential platform
Sartate for GEP NET
I find it hard to believe there won't be multiple interested...
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.04 |
Change
-1.100(15.4%) |
Mkt cap ! $1.934B | |||
| Open | High | Low | Value | Volume |
| $7.10 | $7.10 | $5.92 | $13.25M | 2.065M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 621 | $6.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.06 | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |